Clinical trials: in Austria
Ischemic Stroke, Thrombolysis
Quantitative Net Water Uptake as a Predictor of Functional Outcomes After Intravenous Thrombolysis in Acute Ischemic Stroke International Multicenter Observational Retrospective Study
While the effectiveness of intravenous thrombolysis (IVT) decreases over time, patients show considerable variability in how quickly their ischemic core progresses.
- Trial name
- NCT07299981
- Testing
- No Interventions
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Sigmund Freud PrivatUniversitat
Myeloproliferative Disorders, Myelofibrosis
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus…
- Conditions
- Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
- Trial name
- INDEPENDENCE (NCT04717414)
- Testing
- ACE-536
- Where
- 185 sites in United States, Argentina and 24 more
- Volunteers
- 313 people
- Sponsor
- Celgene
Hematopoietic Neoplasm
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
Primary Objective: To evaluate the efficacy of once daily dose of SAR302503 in subjects previously treated with ruxolitinib and with a current diagnosis of intermediate-1 with symptoms, Intermediate-2 or high-risk primary…
- Trial name
- JAKARTA2 (NCT01523171)
- Testing
- SAR302503
- Where
- 42 sites in United States, Austria and 8 more
- Volunteers
- 97 people
- Sponsor
- Bristol-Myers Squibb
Stroke, Thrombolysis
Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease
Rationale and Relevance: Branch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and…
- Conditions
- Stroke, Thrombolysis, DAPT(Dual Antiplatelet Therapy), SAPT(Single Antiplatelet Therapy)
- Trial name
- NCT07299994
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 462 people
- Sponsor
- Sigmund Freud PrivatUniversitat
Multiple Sclerosis
Validation and Standardization of Paramagnetic Rim Lesion (PRL) Identification in Multiple Sclerosis Across MAGNIMS Centers
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. Paramagnetic rim lesions (PRLs) are a subtype of chronic active MS lesions showing an iron-laden inflammatory rim on…
- Trial name
- NCT07705581
- Where
- 15 sites in Austria, Czechia and 9 more
- Volunteers
- 1,402 people
- Sponsor
- IRCCS San Raffaele
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and < 18 years over a flexible duration.
- Trial name
- Operetta 2 (NCT05123703)
- Testing
- Ocrelizumab, Fingolimod
- Where
- 71 sites in United States, Argentina and 23 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Humerus Pathological Fracture
A Safety and Efficacy Study of the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease
The purpose of this study is to collect safety and performance data of the Photodynamic Bone Stabilization System (PBSS) when used for the treatment of painful impending and actual fractures of the humerus secondary to metastatic…
- Trial name
- NCT02373904
- Testing
- Photodynamic Bone Stabilization System
- Where
- 6 sites in Austria, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- IlluminOss Medical, Inc.
Congenital Heart Disease, Airway Complication of Anesthesia
Video Laryngoscopy Versus Direct Laryngoscopy for Nasotracheal Intubation
The aim of this study is to perform a pilot study investigating the first attempt intubation success rate differing between video laryngoscope nasotracheal intubation and direct laryngoscope nasotracheal intubation.
- Trial name
- NCT05902013
- Testing
- laryngoscopy
- Where
- Austria
- Volunteers
- 152 people
- Sponsor
- Medical University of Vienna
Breast Cancer
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
- Trial name
- OlympiA (NCT02032823)
- Testing
- Olaparib
- Where
- 698 sites in United States, Argentina and 22 more
- Volunteers
- 1,837 people
- Sponsor
- AstraZeneca
Knee Osteoarthristis, Total Knee Replacement
Digitally Supported Short-Term Prehabilitation Before Total Knee Replacement
This study evaluates the feasibility of a short-term, digitally supported prehabilitation program for patients scheduled for elective total knee replacement (TKR).
- Trial name
- P2R-KneeTEP (NCT07621666)
- Testing
- EXERCISE TRAINING WITH OR WITHOUT MEDICATION, Usual Care Group
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Ludwig Boltzmann Institute for Digital Health and Prevention
Urothelial Cancer
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in…
- Trial name
- NCT02516241
- Testing
- MEDI4736 (Durvalumab), Tremelimumab, Cisplatin
- Where
- 222 sites in United States, Australia and 22 more
- Volunteers
- 1,126 people
- Sponsor
- AstraZeneca
Hypoparathyroidism
A Registry for Participants With Chronic Hypoparathyroidism
The main aim of this study is to find out the long-term safety and effectiveness profile of recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) treatment in participants with chronic hypoparathyroidism under conditions of…
- Trial name
- PARADIGHM (NCT01922440)
- Testing
- No intervention
- Where
- 100 sites in United States, Austria and 9 more
- Volunteers
- 1,339 people
- Sponsor
- Takeda
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how…
- Trial name
- NCT02864992
- Testing
- Tepotinib
- Where
- 176 sites in United States, Austria and 13 more
- Volunteers
- 337 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Musculoskeletal Diseases or Conditions
Short- and Medium-term Outcomes of the 3- Versus 4-week PV RehaJET® Rehabilitation Programme
The objective of this observational study is to evaluate and compare the outcomes of two different durations of a recently established work-specific rehabilitation programme in Austria.
- Trial name
- NCT07700017
- Testing
- Multimodal rehabilitation with additional work specific training
- Where
- Austria
- Volunteers
- 499 people
- Sponsor
- Pensionsversicherungsanstalt
Viral Hepatitis
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
- Trial name
- NCT07128550
- Testing
- Tobevibart, Elebsiran, Bulevirtide
- Where
- 38 sites in Austria, France and 5 more
- Volunteers
- 150 people
- Sponsor
- Vir Biotechnology, Inc.
Distal Radius Fractures
DRF Reposition Manual Reduction vs Finger-trap Traction
Participants with distal radius fractures treated conservatively with cast immobilization are assigned to one of two approaches: (1) closed reduction under local anesthesia (hematoma block) followed by traction and casting, or…
- Trial name
- RepoDRF2 (NCT07697976)
- Testing
- Finger-trap traction, Manual reduction
- Where
- Austria
- Volunteers
- 64 people
- Sponsor
- Medical University Innsbruck
Schizophrenia
A Switch Study of BMS-337039 in Schizophrenic Out-patients
The purpose of this clinical research study is to evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general…
- Trial name
- NCT00232687
- Testing
- Aripiprazole
- Where
- 72 sites in Austria, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Aortic Valve Stenosis
Post-Dilatation in Balloon-Expandable TAVI Prostheses
Asymmetrical and inadequate expansion of transcatheter heart valves (THVs) have been described as a key predictor of impaired valve hemodynamic performance predisposing patients for bioprosthetic valve dysfunction (BVD) and…
- Trial name
- DUOTAP (NCT07477002)
- Testing
- Post-dilatation
- Where
- Austria
- Volunteers
- 146 people
- Sponsor
- Medical University of Vienna
Tachyarrhythmia, Heart Failure
BIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs
The CorSky family is BIOTRONIK´s new generation of ICDs. They are the successor devices of the current Acticor/Rivacor family and inherit all iShock/iShock_BC (Ilivia Neo, Intica Neo) implant and programmer software features.
- Trial name
- NCT07360158
- Testing
- CorSky ICD or CRT-D
- Where
- 7 sites in Austria, Czechia and 2 more
- Volunteers
- 151 people
- Sponsor
- Biotronik SE & Co. KG
Cardiovascular Disease, Coronary Artery Occlusion
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
The NAGOMI COMPLEX PMCF (Post-Market Clinical Follow-up) study has been designed to expand the knowledge about outcomes with the Ultimaster Nagomi™ sirolimus eluting coronary stent system (Ultimaster Nagomi™) in complex PCI…
- Conditions
- Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
- Trial name
- NAGOMI COMPLEX (NCT05705973)
- Testing
- Ultimaster Nagomi™
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 3,000 people
- Sponsor
- Terumo Europe N.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.